National Institute for Health and Clinical Excellence (NICE)
NICE recommends novel gene therapy treatment for rare inherited eye disorder
It's estimated that 86 people would be eligible for treatment with voretigene neparvovec in England
A novel gene therapy treatment for rare inherited eye disorder has been recommended by NICE for use on the NHS.
The draft highly specialized technologies guidance recommends voretigene neparvovec (also called Luxturna and made by Novartis Pharmaceuticals UK) for people with vision loss caused by inherited retinal dystrophy from confirmed RPE65 gene mutations and who have enough viable retinal cells.
Voretigene neparvovec is the first licensed gene therapy for vision loss caused by RPE65-meidated inherited retinal dystrophy.
Inherited retinal dystrophies are a group of eye diseases caused by gene mutations which result in the gradual degeneration of the light sensitive cells (photoreceptor cells) on the back of the eye (the retina).
The RPE65 gene provides instructions for making a protein that is essential for normal vision. RPE65-mediated inherited retinal dystrophies are rare and serious. Usually diagnosed in childhood, they involve progressive loss of vision which ultimately leads to near-total blindness and severely affects the quality of life of people with the condition, their families and carers. Current treatment is supportive care, such as the use of low-vision aids.
Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE, said: “This is a highly innovative treatment for a very distressing, inherited condition so we are pleased the company has worked with us and NHS England and Improvement to allow us to offer these families hope for the future.
“The company’s willingness to work with us early and constructively has allowed us to publish this guidance on a much faster timeline than normal which is good news for patients.”
The voretigene neparvovec evaluation at NICE has taken 20 weeks instead of the average of 38 weeks within the Highly Specialised Technologies programme.
Voretigene neparvovec is a gene therapy injected directly into the retina by a surgeon. It works by introducing a healthy copy of the defective RPE65 gene into the retinal cells, enabling people with the condition to produce functional RPE65 protein.
Evidence from clinical trials shows that, in the short term, voretigene neparvovec improves vision and prevents the condition from getting worse. There is no long-term clinical evidence, but the committee considered it is biologically plausible that the treatment effect is likely to continue for decades.
The exact number of people living with the condition is uncertain. The company estimates that 86 people would be eligible for treatment with voretigene neparvovec in England.
Voretigene neparvovec is being recommended for people with inherited retinal dystrophies, after the company worked with NHS England to reach a commercial arrangement which ensured the technology did not breach the Budget Impact Test.
Voretigene neparvovec is the second innovative gene therapy which NICE has produced positive guidance on in its highly specialized technology programme – after Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency was recommended in February 2018.
The list price of voretigene neparvovec is £613,410 per patient. This technology breached the Budget Impact Test, meaning it would have cost the NHS more than £20 million in one of the first three years after being introduced. However, the company has a commercial arrangement with NHS England making the treatment available to the NHS at a discount, the size of which is commercial in confidence.
The draft guidance is now with consultees, including the company, healthcare professionals and patient/carer organisations who have the opportunity to appeal against the draft recommendations. If no appeals are received NICE expects to publish final guidance next month.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Children with rare inherited condition to benefit from drug through managed access agreement12/09/2019 16:25:00
It is estimated that in the UK there are around 30 to 50 children living with the condition.
Applications now open for NICE’s prestigious fellows and scholars programmes12/09/2019 10:15:00
Recruitment for the 2020 intake is open until 28 October 2019
Tailored support should be offered to those affected by suspected suicide, says NICE11/09/2019 09:15:00
Providing support after a suspected suicide can reduce this risk, especially when tailored to the person’s needs.
NICE to work with company on addressing issues in appraisals of cannabidiol for treating difficult to control epilepsies23/08/2019 13:15:00
NICE has today (23 August 2019) announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.
Sir Andrew Dillon to stand down as NICE chief executive22/08/2019 12:15:00
Chief executive has been at the helm of the institute since it was founded in April 1999.
NICE draft guidance and NHS England review highlight need for more research on cannabis-based medicinal products08/08/2019 15:15:00
NICE has today (8 August 2019) published its draft recommendations on the use of cannabis-based medicinal products following a comprehensive evaluation of their clinical and cost-effectiveness
New lung cancer treatment option approved by NICE08/08/2019 12:15:00
Another new life-extending treatment for some people with lung cancer is to be made available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (8 August 2019).
NICE recommends additional treatment option for people with early breast cancer08/08/2019 09:15:00
NICE yesterday (7 August 2019) published a draft guidance recommending neratinib as an additional treatment for some people with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.